Rheumatoid arthritis for cardiologists

Česká verzia

Authors: P. Bradna
Authors place of work: II. interní gastroenterologická klinika a Subkatedra revmatologie katedry interních oborů LF UK a FN v Hradci Králové
Published in the journal: Kardiol Rev Int Med 2017, 19(4): 281-284

Summary

Rheumatoid arthritis is a systemic, inflammatory autoimmune disease, primarily affecting the musculoskeletal system, but also other systems which include the cardiovascular system. Current therapy of the disease is able to achieve remission, with a slowdown or prevention of significant damage in the vast majority of patients. The crucial moment seems a timely initiation of disease-modifying drugs and the achievement of sustained remission or at least low activity of the disease. The most significant cardiovascular aspect of rheumatoid arthritis is the acceleration of atherosclerotic changes as a result of general and rheumatoid-arthritis-specific risk factors. The cardiovascular risk in RA patients is about 1.5 times higher than in the general population and needs to be monitored and treated in a timely manner.

Key words:
rheumatoid arthritis – accelerated arteriosclerosis – therapy – biological therapy

Zdroje

1. Pinheiro FA, Souza DC, Sato EI. A study of multiple causes of death in rheumatoid arthritis. J Rheumatol 2015; 42(12): 2221– 2228. doi: 10.3899/ jrheum.150166.

2. Sparks JA, Karlson EW. The roles of cigarette smoking and the lung in the transitions between phases of preclinical rheumatoid arthritis. Curr Rheumatol Rep 2016; 18(3): 15. doi: 10.1007/ s11926-016-0563-2.

3. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3): 315– 324.

4. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69(9): 1580– 1588. doi: 10.1136/ ard.2010.138461.

5. Smolen JS, Landewé R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease--modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017; 76(6): 960– 977. doi: 10.1136/ annrheumdis-2016-210715.

6. Pavelka K, Vencovský J. Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. Čes Revmatol 2010; 18: 182– 191.

7. Smolen JS, Breedveld FC, Burmester GR et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75(1): 3– 15. doi: 10.1136/ annrheumdis-2015-207524

8. Lazzerini PE, Capecchi PL, Acampa M et al. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev 2014; 13(9): 936– 944. doi: 10.1016/ j.autrev.2014.05.007.

9. Braun J, Krüger K, Manger B et al. Cardiovascular comorbidity in inflammatory rheumatological conditions. Dtsch Arztebl Int 2017; 114(112): 197– 203. doi: 10.3238/ arztebl.2017.0197.

10. Oreská S, Tomčík M. KV riziko u revmatických onemocnění. Cas Lek Cesk 2016; 155(6): 324– 332.

11. Franco AS, Iuamoto LR, Pereira RM. Perioperative management of drugs commonly used in patients with rheumatic diseases: a review. Clinics 2017; 72(6): 386– 390. doi: 10.6061/ clinics/ 2017(06)09.

12. Rempenault C, Combe B, Barnetche T et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2017. pii: annrheumdis-2017-211836. doi: 10.1136/ annrheumdis-2017-211836.

13. Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/ 2016 update. Ann Rheum Dis 2017; 76(1): 17– 28. doi: 10.1136/ annrheumdis-2016-209775.